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TMEM43	 3p25	 transmembrane	protein	43	 Autosomal	dominant	 rare*	DSP	 6p24	 desmoplakin	 Autosomal	dominant	 10-20%	DSG2	 18q12.1-q12.2	 desmoglein	2	 ?Autosomal	dominant	 10-15%	
Dilated	
Cardiomyopathy	
DMD	 Xp21.2	 dystrophin	 X-linked	 ?	DES	 2q35	 desmin	 Autosomal	dominant	 ?	TNNI1	 1q12	 cardiac	troponin	I	 Autosomal	dominant	 ?	





CASQ2	 1p13.3	 calsequestrin	2	 Autosomal	recessive	 rare*	RYR2	 1q42.1-q43	 ryanodine	receptor	2	 Autosomal	dominant	 50-60%	










































































































































































































*	=	Significant	difference,	p<.	05	†=	Fishers	exact	test	used,	expected	cell	count	<5	See	Appendix	D	for	primary	data			 NL	2008	2-40	(A)	 ON	2008	2-40	 Chi-square	value,	significance	(p-value)	
Incidences	Overall	 7.32/100,000	 2.64/100,000	 Χ2=	17.625,	p<.0001*	Ages	2-18	 2.15/100,000	 0.7/100,000	 Χ2=	2.418,	p=	.158†	Ages	19-29	 7.52/100,000	 2.4/100,000	 Χ2=	6.488	p=	.028*†	Ages	30-40	 13.74/100,000	 5.3/100,000	 Χ2=	8.929	p=.008*†	







	 NL	2008	2-50	(B)	 NL	1997	2-50	(C)	 Chi-square	value,	significance	(p-value)	
Incidences	Overall	 13.9/100,000	 16.23/100,000	 Χ2=	.626,	p=.	429	Ages	2-18	 2.15/100,000	 2.32/100,000	 Χ2=	.007,	p=1.00	†	Ages	19-29	 7.52/100,000	 7.70/100,000	 Χ2=	.002,	p=.	969	Ages	30-40	 13.74/100,000	 18.1/100,000	 Χ2=	.486,	p=.	486		Ages	41-50	 32.1/100,000	 43.7/100,000	 Χ2=	1.496,	p=.	221	






















































































































































Cardiac	Disease	 	 Gene	 Locus	 Official	full	name	
Hypertrophic	
Cardiomyopathy	 ACTC1	 15q14		 actin,	alpha,	cardiac	muscle	1		 CALR3	 19p13.11		 calreticulin	3		 CAV3	 3p25	 caveolin	3		 CMH21	 7p12.1-q21		 cardiomyopathy,	familial	hypertrophic,	21			 COA5	 2q11.1	 cytochrome	c	oxidase	assembly	factor	4		 CSRP3	 11p15.1		 cysteine	and	glycine-rich	protein	3		 JPH2	 20q13.12		 junctophilin	2		 MT-ATP6	 --	 mitochondrially	encoded	ATP	synthase	6			 MT-TG	 --	 mitochondrially	encoded	tRNA	glycine			 MT-TH	 --	 mitochondrially	encoded	tRNA	histidine		 MT-TI	 --	 mitochondrially	encoded	tRNA	isoleucine			 MYBPC2	 19q13.33		 myosin	binding	protein	C		 MYBPC3	 11p11.2	 cardiac	myosin-binding	protein	C,	fast	type		 MYH6	 14q12		 myosin,	heavy	chain	6,cardiac	muscle,	alpha		 MYH7			 14q11.2-q12	 β-myosin	heavy	chain		 MYL2	 12q24.11	 myosin,	light	chain	2,	regulatory,	cardiac,	slow		 MYLK2	 20q13.31		 myosin	light	chain	kinase	2	
Hypertrophic	
Cardiomyopathy		
Cont’d	 MYL3	 p21.3-p21.2		 myosin	light	chain	3,alkali;	ventricular,	skeletal,	slow	MYO6	 6q13	 myosin	VI			 MYOZ2	 4q26-q27		 myozenin	2	
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	 TMEM43	 3p25.1	 transmembrane	protein	43	
	 73	
Dilated	
Cardiomyopathy	 ABCC9	 12p12.1	 ATP-binding	cassette,	sub-family	C	(CFTR/MRP	,	member	9		 ACTC1	 15q14		 actin,	alpha,	cardiac	muscle	1		 ACTN2	 1q42-q43	 actinin,	alpha	2		 BAG3	 10q25.2-q26.2	 BCL2-associated	athanogene	3		 CMD1B	 9q13-q22	 cardiomyopathy,	dilated	1B	(autosomal	dominant)			 CMD1H	 2q14-q22	 cardiomyopathy,	dilated	1H	(autosomal	dominant)		 CMD1K	 6q12-q16		 cardiomyopathy,	dilated	1K	(autosomal	dominant)		 CMD1Q	 7q22.3-q31.1		 cardiomyopathy,	dilated	1Q	(autosomal	dominant)		 CRYAB	 11q22.3-q23.1	 crystallin,	alpha	B		 CSRP3	 11p15.1		 cysteine	and	glycine-rich	protein	3		 DES	 2q35	 desmin			 DMD	 Xp21.2	 dystrophin		 DNAJC19	 3q26.33	 DnaJ	(Hsp40)homolog,	subfamily	C,	member	19		 DOLK	 9q34.11		 dolichol	kinase		 DSG2	 18q12.1-q12.2	 desmoglein	2		 DSP	 6p24	 desmoplakin		 EYA4	 6q23	 EYA	transcriptional	coactivator	and	phosphatase	4			 FHL2	 2q12.2	 four	and	a	half	LIM	domains	2		 FKTN	 9q31-q33	 fukutin	
Dilated	
Cardiomyopathy	
Cont’d	 FOXD4	 9p24.3	 forkhead	box	D4		 GATAD1	 7q21-q22		 GATA	zinc	finger	domain	containing	1	
	 74	
	 GJA5	 1q21.1	 gap	junction	protein,	alpha	5,	40kDa		 KCNH2	 7q36.1	 potassium	voltage-gated	channel,	subfamily	H	(eag-related),	member	2			 LAMA3	 18q11.2			 laminin,	alpha	3		 LAMA4	 6q21	 laminin,	alpha	4		 LDB3	 10q22.3-q23.2	 LIM	domain	binding	3		 LMNA	 1q22	 lamin	A/C		 MT-TH	 --	 mitochondrially	encoded	tRNA	histidine		 MT-TY	 --	 mitochondrially	encoded	tRNA	tyrosine			 MURC	 9q31.1	 muscle-related	coiled-coil	protein		 MYBPC3	 11p11.2	 myosin	binding	protein	C,	cardiac		 MYH6	 14q12		 myosin,	heavy	chain	6,cardiac	muscle,	alpha		 MYH7	 14q12	 myosin	heavy	chain	7,	cardiac	muscle,	beta		 MYPN	 10q21.3	 myopalladin		 NEXN	 1p21.1	 nexilin	(F	actin	binding	protein)		 PDCD1	 2q37.3	 programmed	cell	death	1		 PLN	 6q22.1	 phospholamban		 PRDM16	 1p36.23-p33	 PR	domain	containing	16		 PSEN1	 14q24.3	 presenilin	1		 PSEN2	 1q42.13	 presenilin	2		 RAF1	 3p25	 Raf-1	proto-oncogene,	serine/threonine	kinase		
Dilated	
Cardiomyopathy	
Cont’d	 RBM20	 10q25.2	 RNA	binding	motif	protein	20		 RYR2	 1q43	 ryanodine	receptor	2	(cardiac)	
	 75	
	 SCN5A	 3p21	 sodium	channel,	voltage-gated,	type	V,	alpha	subunit			 SDHA	 5p15	 succinate	dehydrogenase	complex,	subunit	A,	flavoprotein		 SGCD	 5q33-q34	 sarcoglycan,	delta	(35kDa	dystrophin-associated	glycoprotein)			 TAZ	 Xq28	 tafazzin		 TCAP	 17q12		 titin-cap		 TMPO	 12q22	 thymopoietin		 TNNC1	 3p21.1	 troponin	C	type	1	(slow)		 TNNI1	 1q12	 troponin	I	type	1	(skeletal,	slow)			 TNNI3	 19q13.4	 troponin	I	type	3	(cardiac)		 TNNT2	 	 troponin	T	type	2	(cardiac)		 TPM1	 15q22.1	 tropomyosin	1	(alpha)		 TTN	 2q31	 titin		 TXNRD2	 22q11.21	 thioredoxin	reductase	2		 VCL	 10q22.2	 vinculin		 ZASP	 7	 ZO-2	associated	speckle	protein	
Long	QT	
Syndrome	 AKAP9	 7q21-q22	 	A	kinase	(PRKA)	anchor	protein	9		 ALG10	 12p11.1	 ALG10,	alpha-1,2-glucosyltransferase		 ANK2	 4q25-q27	 ankyrin	2,	neuronal		 ANKB	 4q25-q27	 ankyrin	B		 CACNA1C	 2p13.3	 l-type	calcium	channel		 CALM2	 2p21	 calmodulin	2	(phosphorylase	kinase,	delta)			 CAV3	 3p25	 caveolin	3		 KCNE1	 21q22.12		 potassium	voltage-gated	channel,	Isk-related	family,	member	1		
Long	QT	
Syndrome	Cont’d	 KCNE2	 21q22.12		 potassium	voltage-gated	channel,	Isk-related	family,	
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	 FKBP1B	 2p23.3	 FK506	binding	protein	1B,	12.6	kDa		 KCNJ2	 17q24.3	 K	inwardly-rectifying	channel,	subfamily	J,	member	2		 RYR1	 19q13.1	 ryanodine	receptor	1	(skeletal)		 RYR2	 1q43	 ryanodine	receptor	2	(cardiac)		 TRDN	 6q22.21	 triadin	
Brugada	
syndrome	 CACNA1C	 2p13.3	 calcium	channel,	voltage-dependent,	L	type,	alpha	1C	subunit			 CACNB2	 10p12	 calcium	channel,	voltage-dependent,	beta	2	subunit			 GPD1L	 3p22.3	 glycerol-3-phosphate	dehydrogenase	1-like		 HCN4	 15q24.1	 hyperpolarization	activated	cyclic	nucleotide-gated	potassium	channel	4			 KCNE3	 11q13.4	 potassium	voltage-gated	channel,	Isk-related	family,	member	3			 SCN1B	 19q13.1	 sodium	channel,	voltage-gated,	type	I,	beta	subunit			 SCN3B	 11q23.3	 sodium	channel,	voltage-gated,	type	III,	beta	subunit			 SCN5A	 3p21-p24	 sodium	channel,	voltage-gated,	type	V,	alpha	subunit	
Short	QT		
Syndrome	 CACNA2D1	 7q21-q22	 calcium	channel,	voltage-dependent,	alpha	2/delta	subunit	1		
Short	QT		
Syndrome	Cont’d	 KCNH2	 7q36.1	 potassium	voltage-gated	channel,	subfamily	H	(eag-related),	member	2			 KCNJ2	 17q24.3	 K	inwardly-rectifying	
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Differences	Current	study	 NL,	Canada	 2008	 2-40	years	 7.32/100,000		 N/A	Current	study	 NL,	Canada	 2008	 2-50	years	 13.9/100,000		 N/A	Current	study	 NL,	Canada	 1997	 2-50	years	 16.23/100,000		 N/A	Pilmer	et	al.,	2013	 ON,	Canada	 2008	 2-40	years		 2.64/100,000	 None	Lim	et	al.,	2010	 British	Columbia,	Canada	 2005-2007	 0-35	years	 1.75/100,000	 No	accidentals	included	Margey	et	al.,	2011	 Ireland	 2005-2007	 15-35	years	 2.85/100,000	 Cases	with	drug	involvement	excluded	Papadakis	et	al.,	2009	 England	and	Wales	 2002-2005	 1-34	years	 1.8/100,000	 No	access	to	autopsy	files,	only	used	office	of	national	statistics	database	Winkel	et	al.,	2011	 Denmark	 2000-2006	 1-35	years	 2.8/100,000	 Used	info	outside	of	autopsy	file	Risgaard	et	al.,	2014	 Denmark	 2007-2009	 1-49	years	 8.6/100,000	 Used	info	outside	of	autopsy	file	and	used	high	number	of	non-autopsy	cases	
36-49	years	 21.7/100,000	
	
